ライフサイエンスコーパス: transarterial

1 ion with Yttrium-90 microspheres is a novel, transarterial approach to radiation therapy.

2 The transarterial catheter was then placed in the same coron

3 cute myocardial infarction (AMI) via a novel transarterial catheter.

4 Transarterial-chemo-embolization (TACE) is used for pall

5 Transarterial chemoembolisation (TACE) is the standard o

6 lus ablation (11.1%), ablation alone (7.9%), transarterial chemoembolization (9.5%), and whole-liver

7 Transarterial chemoembolization (cTACE) has been shown t

8 Conventional transarterial chemoembolization (cTACE) is used to treat

9 ar patient cohort who underwent conventional transarterial chemoembolization (cTACE).

10 ver tumor viability after drug-eluting beads transarterial chemoembolization (DEB-TACE).

11 t patterns including receipt of sorafenib or transarterial chemoembolization (TACE) by HCC-associated

12 outcomes of radiation segmentectomy (RS) and transarterial chemoembolization (TACE) combined with mic

13 on and/or ablation, and 18 were managed with transarterial chemoembolization (TACE) frequently (n = 1

14 Lipiodol-based transarterial chemoembolization (TACE) has been performe

15 induced by transarterial embolization (TAE)/transarterial chemoembolization (TACE) in a state of cel

16 e to guide the decision for retreatment with transarterial chemoembolization (TACE) in patients with

17 sity focused ultrasound (HIFU) combined with transarterial chemoembolization (TACE) in treating pedia

18 Transarterial chemoembolization (TACE) is the main treat

19 treated by radiofrequency ablation (RFA) +/- transarterial chemoembolization (TACE) or surgical resec

20 rine liver metastases (NELM) after the first transarterial chemoembolization (TACE) procedure.

21 Transarterial chemoembolization (TACE) using lipiodol-ba

22 Transarterial chemoembolization (TACE) was similarly app

23 To evaluate safety and efficacy of combined transarterial chemoembolization (TACE) with doxorubicin-

24 (MELD) score >10, and absence of neoadjuvant transarterial chemoembolization (TACE).

25 tumor necrosis after drug-eluting bead (DEB) transarterial chemoembolization (TACE).

26 hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).

27 cellular carcinoma lesions treated with TACE transarterial chemoembolization .

28 Minimally invasive therapies such as transarterial chemoembolization and radiofrequency ablat

29 ing tissue diagnosis, and proven efficacy of transarterial chemoembolization and sorafenib as palliat

30 when combining transplant with preoperative transarterial chemoembolization and/or perioperative sys

31 hepatocellular carcinoma who underwent TACE transarterial chemoembolization before surgery.

32 Each patient underwent two sessions of transarterial chemoembolization between February 2013 an

33 paring yttrium-90 microsphere treatment with transarterial chemoembolization by using the Cancer of t

34 yndrome from Lipiodol embolization following transarterial chemoembolization can occur even with smal

35 odol embolization in a patient who underwent transarterial chemoembolization for hepatocellular carci

36 Transarterial chemoembolization is a widely used therapy

37 Transarterial chemoembolization is accepted therapy for

38 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treat

39 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treat

40 e for the routine utilization of CBCT during transarterial chemoembolization of liver cancer.

41 , respectively, as part of the institutional transarterial chemoembolization protocol).

42 rc cone-beam CT (during the first and second transarterial chemoembolization sessions, respectively,

43 l embolization, intraarterial chemoinfusion, transarterial chemoembolization with or without drug-elu

44 ation, hepatic artery infusion chemotherapy, transarterial chemoembolization, and radioembolization,

45 fore LT with a multimodal approach combining transarterial chemoembolization, liver resection, radiof

46 hepatic resection, radiofrequency ablation, transarterial chemoembolization, transarterial chemoinfu

47 benefit of radical therapies, compared with transarterial chemoembolization, was substantial (5-year

48 long with imaging findings of ablation after transarterial chemoembolization.

49 He progressed following transarterial chemoemoblisation treatment and was commen

50 y ablation, transarterial chemoembolization, transarterial chemoinfusion, yttrium-90 microsphere radi

51 al mesothelioma were treated with repetitive transarterial chemoperfusion between March 2007 and Marc

52 Transarterial chemoperfusion may have the potential to y

53 Transarterial chemoperfusion was performed by using mito

54 cal resection and vascular reconstruction or transarterial coil embolization.

55 Transarterial coronary ethanol ablation can be effective

56 interventions have been assessed, including transarterial embolisation (with or without chemotherapy

57 Transarterial embolization (TAE) has been extensively us

58 visibility of radiopaque microspheres during transarterial embolization (TAE) in the VX2 rabbit liver

59 ay be exploited to potentiate treatment with transarterial embolization (TAE).

60 HCC) cells for surviving ischemia induced by transarterial embolization (TAE)/transarterial chemoembo

61 d advanced interventional procedures such as transarterial embolization and cryoablation are leading

62 c artery ligation (HAL), which recapitulates transarterial embolization in mouse models, to enhance t

63 Transarterial embolization of the gastric fundus with fl

64 Transarterial embolization was planned but repeat cerebr

65 These therapies, which include transarterial embolization, intraarterial chemoinfusion,

66 complications was 10.4% and was highest with transarterial implantation of the Sapien valve (22.3%).

67 data from 463 patients who were treated with transarterial locoregional therapies (chemoembolization

68 r a 9-year period, 285 patients treated with transarterial locoregional therapies underwent scheduled

69 All patients who underwent percutaneous transarterial PDA coil occlusion were studied.

70 ion with 90Y microspheres represents a novel transarterial radiation treatment for liver tumors.

71 ocellular carcinoma (HCC) lesions undergoing transarterial radioembolization (TARE) therapy and to de

72 e hepatocellular carcinoma (uHCC) with (90)Y transarterial radioembolization (TARE) using pretreatmen

73 ed transcatheter arterial chemoembolization, transarterial radioembolization, ablation, and radiother

74 is increasing evidence supporting a role for transarterial radioembolization.

75 ces, Irving, California) implanted using the transarterial route (25.2% vs. 5.0%, respectively).

76 e therapy (HR, 0.63; 95% CI, 0.52-0.76), and transarterial therapy (HR, 0.83; 95% CI, 0.74-0.92) were

77 transplantation, resection, local ablation, transarterial therapy, or sorafenib) and overall surviva

78 upports the use of chemotherapeutic drugs in transarterial therapy.

79 Approaches were transarterial (transfemoral 73%, transapical 18%, subcla

80 Approaches were either transarterial (transfemoral, 74.6%; subclavian, 5.8%; an